Century Therapeutics, Inc. (IPSC)
$1.68+0.17+11.26%Nov 6
Loading chart…
USA›Health Care›Biotechnology›Biotechnology
M.Cap$304M
Dividends—
Next report12 Nov, before open
Forecast
Target
P/E—
P/S—
P/B1.31
5-y avg sales growth+0.0%
Debt / EBITDA12.62
ROE—
Altman Z-score-3.35 (distress)
RSI60
MFI73
Price / MA50-0.0% (med) ↑
Trend pattern
Financial Statements
No data available
Team
Loading…
Leadership Changes
Sign in to view leadership changes
Sign in
No changes found
Insider Activity
Loading…
DateTypeDescription
Loading…
Earnings Transcripts
Loading…
Dividends
Loading…
Investor Presentations
Loading…
Options
Expiration from:
to:
Strike from:
to:
Loading options…
Loading bonds…
Stress Test
Loading…
About

Century Therapeutics develops allogeneic cell therapies to treat various types of cancers, focusing on solid tumors and hematological malignancies. Its lead product is CNTY-101, an allogeneic CAR-iNK cell therapy that targets CD19 for relapsed B-cell lymphoma. The company has also developed several other product candidates for different types of cancers.

https://www.centurytx.com
Beta 1.68